Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.67 Consensus Target Price from Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been assigned an average rating of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $28.6667.

KYTX has been the topic of several research reports. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a report on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Finally, Wells Fargo & Company upped their target price on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th.

Institutional Investors Weigh In On Kyverna Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd bought a new position in shares of Kyverna Therapeutics in the second quarter worth about $37,000. ACT Capital Management LLC bought a new position in shares of Kyverna Therapeutics during the 4th quarter valued at approximately $236,000. Maven Securities LTD bought a new position in shares of Kyverna Therapeutics during the 4th quarter valued at approximately $1,376,000. Monashee Investment Management LLC purchased a new stake in Kyverna Therapeutics in the 4th quarter worth approximately $1,833,000. Finally, Propel Bio Management LLC purchased a new stake in Kyverna Therapeutics in the 4th quarter worth approximately $6,267,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Kyverna Therapeutics Price Performance

Shares of KYTX opened at $7.89 on Tuesday. The firm has a market capitalization of $345.55 million, a P/E ratio of -2.12 and a beta of 3.32. Kyverna Therapeutics has a one year low of $1.78 and a one year high of $13.67. The business has a fifty day moving average of $8.36 and a 200 day moving average of $7.52.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.